Know Cancer

forgot password

A Phase II Trial of Sutent (Sunitinib; SU011248) for Recurrent Anaplastic Astrocytoma and Glioblastoma Multiforme

Phase 2
18 Years
Not Enrolling
Anaplastic Astrocytoma, Glioblastoma

Thank you

Trial Information

A Phase II Trial of Sutent (Sunitinib; SU011248) for Recurrent Anaplastic Astrocytoma and Glioblastoma Multiforme

Trial patients received sunitinib 50 mg daily for 4 weeks without regard to meals, followed
by a 2-week rest period. This 6-week regimen constituted 1 cycle. Patients were treated for
up to 9 cycles [~ year) or until disease progression or death or if persistent toxicities
occurred. Complete blood count with differential, complete metabolic profile, neurologic
exam, and brain magnetic resonance imaging (MRI) with contrast were obtained after each
cycle. Toxicity assessments were obtained after each cycle. Toxicity was graded according to
National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE),
version 3.0.


<14 Days Prior to Initial Study Treatment:

- Neurological/Oncological History

- Neurological Examination

- Height/Weight/Body Surface Area

- Performance Status

- Quality of Life (QOL) FACT-L

- Laboratory Studies; complete blood count (CBC), Differential, Platelets, prothrombin
time/partial thromboplastin time (PT/PTT), international normalized ratio (INR), Serum
Creatinine, blood urea nitrogen (BUN), alanine aminotransferase (ALT), aspartate
aminotransferase (AST), lactate dehydrogenase (LDH), Total Bilirubin, alkaline
phosphatase (AlkPHs), Pregnancy Test, electrocardiogram (EKG)

- Cranial MRI or CT with and without contrast

- Multiple uptake gated acquisition (MUGA) Scan

Day 1, At the Beginning of Each Treatment Cycle:

- Adverse Event Assessment

- Laboratory Studies; CBC, Differential, Platelets

Every Cycle, Days 42-45 (within 3 days of next scheduled Sutent treatment):

- Neurological/Oncological History

- Neurological Examination

- Height/Weight/Body Surface Area

- Performance Status


- Laboratory Studies; Serum Creatinine, BUN, ALT, AST, LDH, Total Bilirubin, AlkPHs

- Cranial MRI or CT with and without contrast

- Survival

At Off Study:

- Performance Status

- Cranial MRI or CT with and without contrast

- Survival

Inclusion Criteria:

- Resolution of all acute toxic effects of prior chemotherapy or radiotherapy or
surgical procedures to NCI CTCAE Version 3.0 grade ≤1.

- Adequate organ function as defined by the following criteria:

- Serum aspartate transaminase (AST; serum glutamic oxaloacetic transaminase
[SGOT]) and serum alanine transaminase (ALT; serum glutamic pyruvic transaminase
[SGPT]) ≤3 x local laboratory upper limit of normal (ULN), or AST and ALT ≤3 x
ULN if liver function abnormalities are due to underlying malignancy

- Total serum bilirubin ≤1.5 x ULN

- Absolute neutrophil count (ANC) ≥1500/µL

- Platelets ≥100,000/µL

- Hemoglobin ≥9.0 g/dL

- Serum calcium ≤12.0 mg/dL

- Serum creatinine ≤1.5 x ULN

- Patients must have histologically or neuroradiographically recurrent anaplastic
astrocytoma (AA) or glioblastoma (GBM). Must have had prior pathologic confirmation
of primary tumor histology.

- Must be ≥ 18 years old.

- Must have a Karnofsky performance status (KPS) ≥ 60%

- Measurable disease per MacDonald criteria required using contrast enhanced cranial

- Life expectancy ≥ 12 weeks.

- Must sign and date an Institutional Review Board (IRB) approved informed consent
stating that he or she is aware of the neoplastic nature of the disease. Must
willingly provide written consent after being informed of procedure to be followed,
the experimental nature of the therapy, alternatives, potential benefits, side
effects, risks, and discomforts.

- Willing and able to comply with scheduled visits, treatment plan, laboratory tests
and accessible for follow-up.

- Have undergone surgery documenting tumor histology though repeat surgery at time of
tumor recurrence is not mandatory.

- Have received prior external beam radiotherapy.

- Patients may have received one or two prior salvage chemotherapy and may have
received adjuvant chemotherapy following initial surgery.

- May not have received prior stereotactic radiotherapy.

- May have been treated with Gliadel at initial surgery only.

Exclusion Criteria:

- Major surgery or radiation therapy within 4 weeks of starting study treatment.

- NCI CTCAE grade 3 hemorrhage within 4 weeks of starting study treatment.

- History of or known spinal cord compression or carcinomatous meningitis, or evidence
of leptomeningeal disease on screening CT or MRI scan.

- Any of the following within 6 months prior to study drug administration: myocardial
infarction, severe/unstable angina, coronary/peripheral artery bypass graft,
symptomatic congestive heart failure, cerebrovascular accident or transient ischemic
attack, or pulmonary embolism.

- Ongoing cardiac dysrhythmias of NCI CTCAE grade ≥2.

- Prolonged QTc interval on baseline EKG.

- Hypertension that cannot be controlled by medications (>150/100 mm Hg despite optimal
medical therapy).

- Pre-existing thyroid abnormality with thyroid function that cannot be maintained in
normal range with medication.

- Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome
(AIDS)-related illness or other active infection.

- Concurrent treatment on another clinical trial. Supportive care trials or
non-treatment trials, e.g. QOL, are allowed.

- Concomitant use of ketoconazole and other agents known to inhibit Cytochrome P450 3A4

- Concomitant use of theophylline and phenobarbital and/or other agents metabolized by
the cytochrome P450 system.

- Ongoing treatment with therapeutic doses of Coumadin (low dose up to 2 mg po daily
for thrombo-prophylaxis is allowed).

- Pregnancy or breastfeeding. Female subjects must be surgically sterile,
postmenopausal, or must agree to use effective contraception during the period of
therapy. Female subjects with reproductive potential must have a negative pregnancy
test (serum or urine) prior to enrollment. Male subjects must be surgically sterile
or must agree to use effective contraception during the period of therapy.

- Other severe acute or chronic medical or psychiatric condition or laboratory
abnormality that may increase the risk associated with study participation or study
drug administration, or may interfere with interpretation of study results, and in
the judgment of investigator would make patient inappropriate for entry into this

- Patients having been treated with 3 or more salvage regimens.

- Patients with a second active malignancy or diagnosis of other cancer within 3 years
of enrollment, except for surgically cured basal cell carcinoma, or in situ carcinoma
of the cervix.

- Mentally incapacitated patients or psychiatric illness that would prevent them from
giving informed consent.

- Poorly controlled diabetes, hepatitis infection, uncontrolled high blood pressure,
unstable angina, symptomatic congestive heart failure, and myocardial infarction
within previous 6 months, or serious uncontrolled cardiac arrhythmia.

- Known to be HIV positive or to have an AIDS-related illness.

- Patients with an active infection that is not adequately controlled with antibiotics.

- Patients with other severe concurrent disease, which, in the judgment of the
investigator, would make the patient inappropriate for entry into this study.

- Known sensitivity to any of the products to be administered during treatment.

- Currently enrolled in another clinical trial or patients who have participated in a
trial of an investigational device or drug within the last 30 days.

Type of Study:


Study Design:

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Number of Participants With Progression Free Survival (PFS) at 6 Months Utilizing McDonald Criteria for Response, Progression and Relapse

Outcome Description:

Complete Response: Disappearance of all lesions, disease signs and symptoms related to the tumor. Partial Response (PR): When compared with pretreatment measurements, a reduction of 50% decrease in the sum of the longest diameters of all target enhancing lesions, taking as reference the baseline sum of the longest diameter. Stable Disease: Neither sufficient shrinkage to qualify for partial response nor sufficient increase to qualify for progressive disease, taking as reference the smallest sum of the longest diameter since treatment started. Objective Progression or Relapse: Relative to pretreatment measurements, an increase in the sum of the diameters of any measured enhancing lesion by at least 25% increase in the sum of the longest diameters since the treatment started or the appearance of new enhancing lesions.

Outcome Time Frame:

6 Months

Safety Issue:


Principal Investigator

Edward Pan, M.D.

Investigator Role:

Principal Investigator

Investigator Affiliation:

H. Lee Moffitt Cancer Center and Research Institute


United States: Institutional Review Board

Study ID:




Start Date:

March 2007

Completion Date:

August 2012

Related Keywords:

  • Anaplastic Astrocytoma
  • Glioblastoma
  • Sutent
  • Astrocytoma
  • Glioblastoma



H. Lee Moffitt Cancer Center and Research Institute Tampa, Florida  33612